Stock GE9 GENMAB A/S
Add to a list
To use this feature you must be a member
Log inSign up

News Genmab A/S BOERSE MUENCHEN

Equities

GE9

DK0010272202

Real-time BOERSE MUENCHEN
Other stock markets
 01:43:39 2024-06-03 pm EDT 		5-day change 1st Jan Change
262 EUR +0.77% Intraday chart for Genmab A/S -0.04% -9.88%
04:19pm Genmab's Tisotumab Shows 'Encouraging' Antitumor Activity in Phase 2 Head, Neck Cancer Study MT
04:00pm Transcript : Genmab A/S - Special Call

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Genmab's Tisotumab Shows 'Encouraging' Antitumor Activity in Phase 2 Head, Neck Cancer Study
MT
Transcript : Genmab A/S - Special Call
Investigational Tisotumab Vedotin Phase 2 Data Demonstrates Encouraging Antitumor Activity in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
BU
Transactions in Connection with Share Buy-back Program
GL
Investigational Tisotumab Vedotin Phase 2 Data Demonstrates Encouraging Antitumor Activity in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
GL
Genmab Announces Initial Data from Phase 2 Cancer Treatment Trial
MT
Preliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Demonstrates 95% Overall Response Rate in Patients with Previously Untreated Follicular Lymphoma
AQ
Preliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Demonstrates 95% Overall Response Rate in Patients with Previously Untreated Follicular Lymphoma
GL
Preliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Demonstrates 95% Overall Response Rate in Patients with Previously Untreated Follicular Lymphoma
BU
Genmab A/S : Investigational Acasunlimab (DuoBody® PD L1x4 1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non small Cell Lung Cancer (mNSCLC)
PU
Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)
BU
Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)
GL
Transactions in Connection with Share Buy-back Program
GL
Genmab to Showcase Data in Various Patient Populations to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting
BU
Genmab to Showcase Data in Various Patient Populations to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting
GL
Genmab Completes Acquisition of ProfoundBio
BU
Genmab Completes Acquisition of ProfoundBio
GL
Genmab A/S Reaffirms Financial Guidance for 2024
CI
Transactions in Connection with Share Buy-back Program
GL
Genmab A/S completed the acquisition of ProfoundBio, Inc.
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. GMAB Stock
  4. GE9 Stock
  5. News Genmab A/S